Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
R&D The SPC waiver: How do we restore the intended balance betwe... Biosimilars promote cost-effective solutions to critical healthcare challenges.
Views & Analysis Huge scale of Brexit threat to Europe’s medicines supplies r... New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
News Lilly strikes $1.9bn kidney disease alliance with Ascidian In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.